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ABSTRACT
Leigh syndrome is the most common mitochondrial disease, affecting
1:40,000 live births. It manifests with symptoms including ataxia, cognitive
impairment, motor difficulties, and stroke. Leigh syndrome is a genetic condition
caused by mutations in either the nuclear DNA or mitochondrial DNA that affects
the assembly of the electron transport chains. Death typically occurs around 2-3
years of age, due to respiratory failure, as the body cannot produce sufficient ATP
for survival. The genetic basis of Leigh syndrome means that there is no cure, and
current treatments of the symptoms have proven ineffective. This thesis proposes
two different therapeutic approaches for Leigh syndrome. The Ndufs4 knock-out
(KO) mouse is an animal model of Leigh syndrome, and is the result of a mutation
in complex I of the electron transport chain. This leads to symptoms almost
identical to human patients including necrotizing lesions, seizures and motor
impairments. The pathology in this model is associated with oxidative stress,
protein succination, and inflammation. The therapeutic interventions selected are
aimed at reducing these factors and the role that they play in disease progression.
N-acetylcysteine amide (NACA) is a precursor for glutathione, a powerful
cellular antioxidant involved in the reduction of oxidative stress. In this study we
administered NACA for 14 days and examined the effect on motor coordination in
the mice. In addition, we examined the levels of a protein modification (protein
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succination) that is derived from the reaction of fumarate with protein thiols and is
increased in the affected brain regions. We observed an improvement in the fine
motor coordination in the mice receiving NACA for 14 days, highlighting the
potential utility of this treatment; however, we did not detect reductions in oxidative
stress markers or protein succination in association with this improvement.
Patients with Leigh syndrome display increased neuroinflammation and, in
a similar manner, the Ndufs4 KO mouse also displays increased immune cells,
particularly microglia, congregated in and around these lesions. PLX5622 is a
microglial depletion drug and we hypothesized that decreasing the microglial
content would decrease the inflammation, and contribute to improved survival and
behavioral improvements. We also proposed that it may reduce protein succination
in the brainstem as increased succination has recently been associated with
macrophage activation. Overall, PLX5622 administration did not appear to be
beneficial for the course of the pathology in the Ndufs4 KO mice, perhaps in part
due to the severity of their symptoms and the need for some functional microglial
presence to remove dying neurons.
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CHAPTER I
INTRODUCTION
1.1 Mitochondrial Respiration
Mitochondria are the “power-houses” of the cell, providing the body with
~90% of cellular ATP via oxidative phosphorylation (OXPHOS) in all nucleated
cells (1, 2). OXPHOS describes electron transfer through a series of
oxidoreductase reactions known as the electron transport chain (ETC), coupled to
the phosphorylation of ADP to ATP (Figure 1.1) (3, 4). The ETC consists of 5
complexes that are embedded in the inner mitochondrial membrane, with electrons
entering through complex I and/or II via NADH and/or FADH2, respectively. The
electrons entering through complex I and/or II are transferred through the chain to
reduce O2 to H2O at complex IV (3). Protons are simultaneously pumped at
complexes I, III and IV from the matrix into the intermembrane space, creating an
electrochemical gradient. Complex V (ATPase), also known as ATP synthase,
uses the energy from protons re-entering the matrix, via the ATPase, to produce
ATP from ADP and inorganic phosphate (3, 5).
Mitochondria are also responsible for the production of reactive oxygen
species (ROS). Under normal physiological conditions, the mitochondria produce
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a basal level of ROS that can be involved in cell signaling, however, a disturbance
in the ETC can cause an increase in the level of ROS produced, leading to
oxidative stress (6). The reactive oxygen species hydrogen peroxide (H2O2) and
superoxide are not necessarily toxic due to the presence of the antioxidant defense
enzymes glutathione peroxidase and superoxide dismutase. However, when
present in excess, they can react with metal ion catalysts and are further converted
into hydroxyl radicals that react rapidly with intracellular proteins, lipids, and DNA,
causing protein aggregation, lipid peroxidation, and DNA hydroxylation (7, 8). Free
radical induced lipid peroxidation has been shown to also produce a variety of
cytotoxic aldehydes, including 4-hydroxynonanal (HNE), whose adducts on
proteins are commonly examined biomarkers of oxidative stress (7-9). Protein
carbonylation refers to protein oxidation by ROS, with amino acid side chains
forming reactive aldehydes, further reacting to cause aggregation and crosslinking
(10). Intracellular stress caused by carbonylation may result in biomolecular
malfunction and increased toxicity, leading to apoptotic cell death (11, 12). The
accumulation of carbonylated proteins has been associated with affected brain
regions of certain neurological disorders, particularly Alzheimer’s disease (12).
1.2 Mitochondrial Respiratory Chain Disorders
Mitochondrial respiratory chain disorders refer to conditions that are due to
mutations in either nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) that
impact the efficiency of OXPHOS, and occur in a wide range of encephalopathies
and myopathies (13, 14). Mutations in the mtDNA can be the result of point
mutations, deletions, or large-scale rearrangements (15). While they are rare
2

individually, together these diseases occur with a prevalence of ~1:5000 (16). A
mutual feature is a failure to thrive due to the lack of energy production in cells,
specifically in organs that require more energy, such as muscle, brain, and the
heart (17). Seizures are one of the most widely observed symptoms and occur in
approximately

30-60%

of

the

individuals

with

biochemically

confirmed

mitochondrial diseases (MDs), due to mitochondrial epilepsy (18-20). This is
usually part of a larger, multi-system disorder, occurring in both early- and lateonset MD (18, 21).
The well characterized MDs are Leber’s Hereditary Optic Neuropathy
(Leber’s), Kearns-Sayre Syndrome (KSS), Mitochondrial Encephalomyopathy,
Lactic Acidosis, and Stroke-like episodes (MELAS), Myoclonus Epilepsy with
Ragged Red Fibers (MERRF), and Leigh Syndrome (LS). Leber’s, also known as
LHON, is a maternally inherited mtDNA disease that can cause blindness (22).
Leber’s is commonly due to primary or secondary mitochondrial dysfunction that
affects retinal ganglion cell survival (23). Classically, symptoms begin suddenly
around 15 to 35 years of age with the onset of central visual loss (24). The disease
occurs predominantly in males, with loss of vision typically beginning in one eye
and moving on to the second (bilateral) within a year (24, 25). There are three point
mutations in mtDNA that are believed to lead to 90-95% of the cases of LHON
known as ‘primary’ LHON mutations (26).
Kearns-Sayre Syndrome (KSS) is one of three phenotypes caused by
single-deletions or duplications in mtDNA (27). As a multi-system disorder, KSS
displays progressive external ophthalmoplegia and pigmentary degeneration of
3

the retina, with ~50% of cases displaying cardiac involvement (28). Cardiac
conduction blocks occur in varying degrees of severity, with polymorphic
ventricular tachycardia being the most common (29).
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
(MELAS) syndrome is one of the most common MDs. It is maternally inherited and
has most commonly been attributed to a transition of adenine to guanine in
nucleotide 3243 of mtDNA (2, 30, 31). MELAS patients show signs of dementia,
muscle weakness, and epilepsy (2). The dementia is caused by both the cortical
injuries and stroke-like episodes, resulting in neural difficulties including problems
with language, perception, and memory function (2, 32).
Myoclonus epilepsy with ragged red fibers (MERRF) syndrome is an
inherited MD with a prevalence of approximately 1:400,000 (33, 34). 80-90% of
these cases are caused by an A8344G mutation in the mtDNA tRNALys gene (3537). Affecting mainly the nervous system and skeletal muscles, MERRF is known
to cause myoclonus, muscular atrophy, epilepsy, and ataxia (38, 39). The defining
characteristic of this disease is the ragged-red fibers in the muscles, containing
subsarcolemmal aggregations of abnormal mitochondria; however, these muscle
fibers have been seen in other MDs, such as KSS and Leigh Syndrome. Raggedred fibers are not typical of muscle and are seen as “myopathic”, with patients
diagnosed with MERRF exhibiting ~12-13% ragged-red fibers in their muscles (39,
40).
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1.3 Leigh Syndrome
The most common MD is Leigh Syndrome (LS), occurring in approximately
1 in 40,000 live births (41). Linked to over 75 gene mutations, LS is a devastating
neurodegenerative

disorder

(42,

43).

LS

was

discovered

by

British

neuropathologist Denis Leigh in 1951, when a 7 month old infant was admitted
with encephalomyopathy and respiratory difficulties. Symptom onset began
approximately six weeks prior to death and caused intense drowsiness, blindness,
deafness, and spasticity of his limbs. During autopsy, the child’s brain showed
lesions, vascular overgrowth, acute cellular swelling, and increased microglial
presence (44). The onset of symptoms in LS normally occur in infancy, however,
there have been cases of adult onset reported (45). Very few patients survive past
the age of 10 years-old (43). Soufu et al. described a median onset age of 7
months, with 80.8% of patients displaying symptoms by 2 years-old. Predictors of
poor survival were seen as symptoms occurring at or under 6 months of age, failure
to thrive, brainstem (BS) lesions, and requirement of intensive care (45). LS is now
characterized by bilateral necrotizing lesions in the basal ganglia (BG), thalamus
and BS, as well as respiratory failure, seizures, ataxia, cognitive impairment, and
stroke (46). Biochemically, LS results in lactic acidosis, ensuing from the
accumulation of pyruvate due to elevated levels of NADH. There have been
reported increases in lactate and lactate:pyruvate ratios in blood, urine, and
cerebrospinal fluid of patients (43). This increase in lactate has been displayed in
all organs in the body with mitochondrial deficiency, particularly in the liver (47-49).
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Increased lactate in cerebrospinal fluid has been associated with a severe disease
course (44).
LS is most frequently the result of a mutation that leads to the impaired
assembly of one of the five complexes of the ETC, but most commonly complexes
I or IV (50). There have also been a number of cases reporting dysfunction in
coenzyme Q or the pyruvate dehydrogenase complex as the cause of LS (43).
Complex I is the largest complex of the OXPHOS system, with 45 different subunits
folding together to create a large (980kD), L-shaped component (3, 51). This
complex removes electrons from NADH to transfer them to ubiquinone, where they
continue through the ETC. Approximately 30% of the defects in complex I are
caused by a mutation in the mtDNA, most frequently MTND1, MTND3, and MTND5
(52). Nuclear DNA mutations also contribute to LS. Assouline et al. described
NADH:Ubiquinone oxidoreductase subunit S4 (NDUFS4) mutations that result in
fatal, early-onset mitochondrial disease, specifically Leigh syndrome (53). Ndus4
is a relatively small (18kD), nDNA-derived assembly protein that is believed to
assist in the establishment of the tertiary structure of complex I, once Ndufs4 is
phosphorylated (53-55). Loss of Ndufs4 causes complex I to form a smaller (~830
kD) subcomplex that lacks NADH dehydrogenase (Figure 1.2) (56, 57). This is
detrimental for optimal complex I activity, decreasing the amount of NADH that can
be oxidized to NAD+. This subsequently reduces the levels of ATP generated by
the ETC, as well as potentially increasing the number of ROS generated (57).
The Ndufs4 knock-out (KO) mouse is used as an animal model of LS as it
exhibits many of the same characteristics as the human disease (58-60). The
6

mouse was first described by Kruse et al. with a deletion of exon 2 causing a
frameshift mutation halting the synthesis of the mature protein (58). The complete
KO of complex I activity would most likely lead to embryonic death, yet the Ndufs4
KO mouse survives for a limited lifespan, therefore the OXPHOS system must be
able to compensate for this defect. Calvaruso et al. demonstrated that the Ndufs4
KO mouse was able to survive due to the formation of a novel supercomplex. This
supercomplex is formed between the partially assembled complex I and the fully
functioning complex III, causing complex I to stabilize and allowing electrons to be
transferred to ubiquinone (56). The phenotype of the KO mice was distinguishable
from their wild-type (WT) littermates beginning at approximately postnatal day 21
(p21), and the KOs die ~p50 (58). Quintana et al. verified that these mice
experienced cognitive impairment, ataxia, respiratory distress, and defects in
vision, all of which are symptoms of LS in humans (56). Light microscopy and
electron microscopy have been used to visualize the pathological changes in brain
regions that correspond to the deteriorating health of the mice, namely the BS and
cerebellum (CB). The degree of gliosis and lesion development in these regions is
similar to humans with LS. A significant difference in the mouse model and the
human disease is that the basal ganglia (BG) appears to be unaffected in the KO
mice (59).
1.4 Mechanisms Contributing to the Pathology of Leigh Syndrome
In addition to the reduced production of neuronal mitochondrial ATP,
oxidative stress has been described to be increased in the fibroblasts of patients
with LS due to a mutation in complex I. These fibroblasts had significantly
7

increased levels of H2O2, as well as superoxide anion radicals in the mitochondria.
There was also evidence of increased protein carbonylation in these fibroblasts,
indicating cumulative oxidative damage. These patients were further observed to
have decreased antioxidant protection with lower levels of the enzymes catalase
and superoxide dismutase 1 and 2 (61). Mitochondrial epilepsy has been linked to
both ATP depletion in the brain, as well as oxidative stress. Epileptogenesis is
characterized by neuronal hyperexcitability, which may be triggered by increased
ROS production above what is required for synaptic signaling (62).
Beyond the detection of lactic acidosis biochemically, the diagnosis of Leigh
Syndrome is often performed via magnetic resonance imaging (MRI) which inicate
bilaterally symmetric lesions, particularly in the BG, BS, and CB, before moving to
genetic testing (63, 64). Microglia have been discovered to congregate at the
periphery of these lesions, often in large numbers (44, 65). Microglia are the
immune cells of the brain, comprising roughly 12% of cells, predominantly in the
gray matter (66, 67). In a typical brain, these cells are at rest unless they are
activated by events such as environmental stress or immunological challenges.
Once activated, they undergo morphological and functional transformations to
perform a diverse number of functions, such as phagocytosis of dying neurons and
facilitating repair at the sight of inflammation and/or injury (67-69). However, in
neurological disease, microglia can become over-activated and have been
implicated in leading inflammation-mediated neuronal damage. These cells create
a neurotoxic environment through the excess production of pro-inflammatory
cytokines, as well as cytotoxic factors, such as superoxide (67, 68). This leads to
8

inflammation, particularly where the microglia are congregated around the lesions
(44, 70). Quintana et al. demonstrated that complex I dysfunction in the Ndufs4
KO is associated with the activation of glial cells, and further proposed that this
leads to oxidative stress, cytokine release by microglia, and ultimately neuronal
death via the extrinsic apoptotic pathway (59).
S-(2-succino)cysteine (2SC) formation, also termed protein succination,
refers to the reaction of fumarate with the thiol group on protein cysteine residues,
generating an irreversible chemical modification (Figure 1.3) (71). Fumarate levels
must be significantly heightened for this reaction to occur, and increased fumarate
and protein succination has been described in adipocytes and obesity, as well as
hereditary leiomyomatosis and renal cell cancer syndrome (72-76). Interesting,
Barshop et al. reported increased fumarate and malate levels in the urine of
patients with mitochondrial diseases (77), suggesting that elevated fumarate and
protein succination may also have a role in the pathology of LS progression. As
the ETC cannot function properly, NADH cannot be oxidized to NAD+, leading to
an accrual of NADH and shortage of NAD+, inhibiting NAD+-dependent
dehydrogenases and leading to the accumulation of fumarate and other Krebs
cycle metabolites (14, 78). Piroli et al. demonstrated that protein succination is
increased predominantly in the BS, olfactory bulbs (OB) and CB of the Ndufs4 KO
mice (Figure 1.4). This was particularly increased in the vestibular nucleus (VN), a
region of the brainstem that plays a significant role in motor coordination (Figure
1.4) (14). Protein succination has been shown to decrease the functionality of the
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proteins modified (79, 80), suggesting that succination in the brain of the KO mice
may also cause further damage to the already compromised mitochondria (14).
Overall, in addition to the existing bioenergetics defect, the combined insults
of oxidative, metabolite and inflammatory stress appear to be significant
contributors to the progression of neuropathology in this model of LS. Despite this,
the precise mechanisms linking the bioenergetics defect to neuronal cell death
remain to be fully elucidated.
1.5 Therapeutic Treatments for Leigh Syndrome
There are over 75 different gene modifications that are responsible for LS,
resulting in variable patterns of disease progression and symptom severity. Since
there is no cure for this disease, physicians often face difficulty in generating an
effective treatment plan. The typical treatment approach revolves around a cocktail
of vitamins and supplements, such as coenzyme Q10 (CoQ10) and its derivatives
(81, 82). CoQ10, or ubiquinone, is an electron carrier from complex I and II to
complex III of the ETC (82, 83). In a patient with limited complex I activity, CoQ10
may be administered in an attempt to bypass complex I via reducing equivalents
entering the ETC through complex II and the oxidation of succinate, followed by
transfer to complex III via CoQ10 (82, 84, 85). In its reduced form of ubiquinol, this
directly acts as an antioxidant by preventing the initiation or propagation of lipid
peroxidation (84). There are also indirect antioxidant properties of this coenzyme
as it regenerates vitamins C and E, both of which may act as antioxidants (85).
While the idea of ubiquinone as a treatment is practical, studies have shown
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controversial results of CoQ10 as a treatment of mitochondrial disease (85-87).
García-Corzo et al. demonstrated a water-soluble formulation of CoQ10 that
reduced oxidative damage and increased body weight in Coq9x/x mice, but did not
completely rescue the encephalopathic phenotype (85).
In addition to CoQ10 treatments, riboflavin (B2) and folinic acid (B9) are
frequently administered to LS patients. Riboflavin is believed to be useful in
complex I deficiency due riboflavin being present in flavin mononucleotide (FMN).
FMN is a prosthetic group of complex I, and has been documented as lacking in
the muscle of patients with complex I deficiency (88, 89). Folinic acid is given to
patients who suffer from central nervous system (CNS) manifestations (90). It is a
reduced form of folic acid, and involved as a cofactor in many metabolic reactions
(91).
The common treatments for LS are not necessarily effective, nor do they
provide a long term cure, therefore, new, alternative therapeutic practices are
being studied. Rapamycin is an inhibitor of the mechanistic Target of Rapamycin
(mTOR), and has been proven to increase lifespan in multiple models of different
organisms (92-95). mTOR has functions in 2 complexes, mTORC1 and mTORC2,
with rapamycin reacting with mTORC1. One of the main functions of mTORC1 is
the promotion of mRNA translation and protein synthesis, with mTORC1 also
helping to regulate autophagy. However, the activity of this pathway decreases as
age increases. It is known that inhibition of mTORC1 increases autophagy,
allowing the body to dispose of aged cells, therefore, its inhibition is believed to
assist in slowing the aging process (94). A study by Johnson et al. investigated the
11

effects of rapamycin in Ndufs4 mice in order to distinguish if the longevity given by
rapamycin would assist the KO mice past their normal maximum age of ~P50.
Daily intraperitoneal injections were administered to the mice, allowing for an
extension of life from ~P50 up to a maximum of P269. The treated mice did not
display the signature lesions that age-matched, vehicle-treated mice did, nor did
their behavior worsen as quickly with age. Unfortunately, this treatment does
display some adverse effects, including immunosuppression, hyperlipidemia, and
slow wound healing, all of which could prevent its use (96).
Recently, Jain et al. used a Cas9-mediated knock-out screen to examine
~18,000 genes in an effort to find a genetic factor for suppressing MD (81). Von
Hippel-Lindau factor (VHL) was identified as the most effective factor in both
severe and moderate diseases. VHL is a key factor in the regulation of the hypoxic
pathway; a ubiquitin ligase that targets hypoxia-inducible transcription factors (HIF)
for degredation. When VHL is knocked out, HIF is stabilized and the cells can
bypass cellular oxygen sensing mechanisms. VHL-knock-out cells were found to
be more resistant to complex I and complex V ETC dysfunction. To further
translate this, Ndufs4 KO mice were treated with chronic moderate environmental
hypoxia (11% O2), preventing development of many of the symptoms of LS, as
well as extending life-span (81). This study was expanded upon and found that
while their average normoxia-treated KO died ~P60, hypoxia-treated KO mice
survived until ~P270 (97). The primary disadvantage to this treatment option is that
hypoxia must be chronic, as intermittent hypoxia of 10 hours a day does not yield
the same results. Furthermore, once mice are returned to normoxia from hypoxic
12

conditions, they die within a few days (97), therefore the practical application of
hypoxia treatment for LS patients remains under investigation. This thesis will
focus on two alternative treatments for LS that may have a more practical
application, and may reduce or prevent some of the biochemical contributors to
the pathology discussed above.
Chapter 2 will investigate the utility of N-Acetylcysteine Amide (NACA), a
precursor to the cellular antioxidant glutathione, in the treatment of LS. I propose
that NACA will decrease oxidative stress by increasing the amount of glutathione
in the cells, thereby decreasing ROS generation and protein oxidation. I also
expect a decrease in succination, as the thiol group of NACA may react directly
with available fumarate. Therefore, NACA may be dually beneficial in preventing
both oxidant and metabolite derived cellular stress.
Chapter 3 will investigate the use of microglial depletion in the Ndufs4 KO
brain via PLX5622 (PLX). As the KO mice have an increased level of microglia
compared to their WT littermates, I hypothesize that reducing the quantity of
microglia will diminish the inflammation in KO brains. This will lessen the
neurological symptoms, resulting in a longer lifespan, as well as increased motor
coordination.
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Cytoplasm

Figure 1.1 Electron Transport Chain (ETC). Flow of electrons and protons
through the ETC from complex I through complex V (ATPase) (4).
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Figure 1.2 Complex I assembly. A) Displays the portion of the complex that
provides the NADH dehydrogenase function. This portion includes Ndufs4. B)
Assembly of the different subcomplexes contained in complex I. Ndus4 is located
in the final subcomplex, allowing for the finalized structure of complex I and its
NADH dehydrogenase function (57).
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Figure 1.3 Formation of S-(2-succino)cysteine (2SC). Protein thiols react with
excess fumarate, forming an irreversible protein modification, S-(2succino)cysteine (2SC).
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Figure 1.4 Detection of Protein Succination in the Vestibular Nucleus (VN)
of the Brainstem. VN extracts of Ndufs4 WT and KO mice was probed with anti2SC antibody to display a significant increase in succination of the VN of KO
mice versus WT, particularly in VDAC1, VDAC2 and α-tubulin (14).
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2.1 Introduction
Leigh syndrome (LS) is a mitochondrial respiratory chain disorder
characterized by bilateral necrotizing lesions in the basal ganglia, thalamus and
brainstem (BS), as well as seizures, ataxia, cognitive impairment, and stroke (44,
45). Biochemically, lactic acidosis results from the accrual of pyruvate, as well as
elevated levels of NADH, with increased lactate in cerebrospinal fluid associated
with a severe disease course (43). As LS is commonly due to a mutation in
complex I of the electron transport chain (ETC), the Ndufs4 knock-out (KO) mouse
has been developed to model LS, displaying many of the common features of the
human disease, including bilateral necrotizing lesions, ataxia, and respiratory
distress (59). NADH:Ubiquinone oxidoreductase subunit S4 (Ndufs4) is an
assembly protein that participates in the formation of the tertiary structure of
complex I. The Ndufs4 KO mouse removes the NDUFS4 gene, resulting in the
abolishment of the NADH dehydrogenase activity of complex I (56).
Mechanistically, the mitochondrial dysfunction observed is associated with
increased oxidative stress, as evidenced by an increase in hydrogen peroxide
(H2O2) and superoxide anion radicals in the mitochondrial matrix of fibroblasts from
patients with confirmed LS (61) The fibroblasts from these patients were also
observed to possess decreased antioxidant protection, including lower levels of
enzymes involved in the “neutralization” of the reactive oxygen species (ROS) (61).
While Kayser et al. did not notice significant changes in the concentration of ROS
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in Ndufs4 KO mice vs WT (98), Koopman et al. displayed an increase in ROS of
patients with a complex I deficiency, furthering this via a secondary experiment
exposing increased ROS in Ndufs4 KO mice (99, 100).
In addition to oxidative stress, we have recently described increased protein
succination in the BS, olfactory bulbs (OB), and CB of the Ndufs4 KO mouse (14).
Succination is derived from the spontaneous reaction of fumarate with the thiol
group on protein cysteine residues, resulting in an irreversible chemical
modification to form S-(2-succino)cysteine (2SC) (71, 72). Amplified levels of the
metabolites fumarate and malate have previously been described in the urine of
patients with mitochondrial diseases (73). In the Ndufs4 KO mice, this increase in
fumarate is driven by the accumulation of NADH due to impaired complex I
function, resulting in the inhibition of NAD+-dependent enzymes in the Krebs cycle
(14).
The tripeptide glutathione (GSH) functions as a potent antioxidant, as well
as being necessary for the synthesis of other antioxidants, and exists in both
reduced (GSH) and oxidized (GSSG) forms (101-103). Evidence has suggested
that dysfunctional GSH homeostasis is implicated in various diseases including
neurodegeneration and brain aging (104). N-acetylcysteine (NAC) has been used
as a precursor to endogenous GSH, and has been established to have beneficial
effects on diseases initiated by oxidative stress (105-109). However, NAC has low
lipid solubility and tissue distribution, failing to provide significant antioxidant
effects in vivo due to the loss of a proton by its carboxylic group at physiological
pH, producing a negative charge (109, 110). In order to combat this, N20

acetylcysteine amide (NACA) was developed, replacing the carboxyl with an amide
group. This modification allows NACA to cross membrane barriers, such as the
blood brain barrier, and be more effective at lower concentrations (111).
Recently, Liu et al. described an increase in oxidative stress and lipid
accumulation as early disease markers in Drosophila models of mitochondrial
dysfunction. To counter this, they demonstrated that NACA administration offered
therapeutic benefit in both the Drosophila models and Ndufs4 KO mice. NACA
administration for 7 days, beginning at postnatal day 21 (p21), delayed the onset
of symptoms and reduced their severity throughout the lifespan of the Ndufs4 KO
mice (105).
Fumarate reactivity with GSH has previously been described in models of
fumarate hydratase deficiency where fumarate levels are significantly elevated and
this has, in turn, increased production of ROS (112-114) Considering that excess
fumarate may also directly react with the cysteine of NACA, we propose that NACA
may offer additional benefit by decreasing protein succination in addition to
reducing oxidative stress. Therefore, we hypothesized that extended, 14 day
NACA treatment of 150 mg/kg/day in the Ndufs4 KO model might improve motor
co-ordination in the mice, and reduce markers of mitochondrial stress including
both oxidant and fumarate stress.
2.2 Results
Both NAC and NACA have previously been shown to increase the
glutathione (GSH) content in cells during cellular stress (108-111). To confirm that
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NACA may act in a cytoprotective manner, we exposed mature cortical neurons to
dimethyl fumarate (DMF) for 5 hours. DMF rapidly induces a mild oxidative stress
through the covalent modification of reduced GSH, which in turn activates several
antioxidant response element genes (111, 115). Figures 2.1A & 2.1C demonstrate
a pronounced decrease in the reduced GSH content following 5 hours of exposure
to 100 µM DMF. Pre-treatment with either 5 mM NAC or NACA for 24 hrs
completely protected the cells from the DMF induced depletion of GSH (Figure
2.1A, 2.1C, (p<0.001)). Oxidized glutathione (GSSG) levels were also reduced
upon DMF treatment, but not in the cells treated with NAC or NACA (Figure 2.1B,
1D, (p<0.001)). These results confirm that DMF directly reduces cellular GSH
content, leading to lower total levels of both GSH and GSSG. In addition to
potentially increasing the GSH content, the pre-treatment with NAC and NACA
would provide available thiols that DMF directly modifies, potentially sparing
cellular GSH from direct modification.
Previously, a 7 day intervention with NACA in Ndufs4 knock-out (KO) mice
versus wild-type (WT) littermates was shown to reduce the severity of clinical
symptoms, as well as a delayed latency to fall from the rotarod (105). We
hypothesized that extending NACA administration for a total of 14 days might
further improve motor co-ordination skills in the Ndufs4 KO mice. Following
weaning at 21 days of age, habituation and testing were performed between 23
and 28 days of age. The mice were subsequently administered daily intraperitoneal
injections of NACA for 14 days. The body weights of the KO mice decreased in
association with the disease progression over the study period versus WT control
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mice, and there was no significant effect of NACA treatment on body weight
(Figure 2.2).
Fine motor co-ordination skills were evaluated on an inclined balance beam,
with the untreated KO mice demonstrating significant impairment in their latency
to traverse the beam between initial tests and those performed at the end of the
study (KO Pre vs Post, Figure 2.3A, (p<0.001). Following the intervention period,
KO mice were approximately three times slower than WT or WT + NACA in the
average time to cross the beam, (WT vs KO, Post, Figure 2.3B, (p<0.001)),
confirming a loss of fine motor skills. In contrast, KO + NACA mice did not display
a significant variation in their speed (KO + NACA Pre vs Post, Figure 2.3A). The
NACA treated KO mice traversed the beam significantly faster than the saline
injected KO mice (KO vs KO + NACA, Post, Figure 2.3B, (p<0.05)).
The number of paw slips (for any paw) that occurred while traversing the
beam were also counted (Figure 2.3C). Both the KO and KO + NACA mice both
had a significantly increased number of paw slips in comparison to the WT and WT
+ NACA groups, indicative of impaired ability to balance. However, the KO + NACA
mice had significantly fewer paw slips compared to the untreated KO mice (KO vs
KO + NACA, Post, Figure 2.3C, (p<0.001)), indicating that NACA treatment also
improved this aspect of subtle coordination and balance.
The co-ordination and endurance of the mice was also assessed in their
latency to fall from the rotarod. Figure 2.4A demonstrates the difference in time to
fall from the accelerating rod for each group of mice over the course of the study.
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The KO and KO + NACA treated mice both fell from the rotarod significantly faster
at the end of the study versus the initial testing period (KO pre vs post (p<0.001),
KO + NACA pre vs post (p<0.001), Figure 2.4A). During the final trials, KO mice
were only able to remain on the wheel for half the time of the WT mice (KO vs WT
(p<0.001), KO + NACA vs WT (p<0.05), Figure 2.4B). However, unlike the balance
beam, a significant improvement was not detected for the KO mice receiving NACA
on the rotarod performance compared to untreated KO.
Since NACA treatment preserved neuronal GSH content in vitro (Figure
2.1), an increase in the amount of reduced GSH in the olfactory bulb following
NACA administration in vivo for 14 days was predicted. There was not a significant
difference between the levels of GSH in WT versus KO mice (Figure 2.5A),
although there was a slight trend for decreased GSH. This included a decrease
between WT control mice and KO control, as well as KO + NACA mice having a
lower concentration of GSH than KO control mice. There was also a trend for the
GSSG:GSH ratio to be increased in the KO mice versus WT (Figure 2.5B).
Unexpectedly, the KO + NACA olfactory bulbs contain less GSH than KO control
(Figure 2.5A, p<0.05). GSH protein adducts in the BS of the mice were also
assessed by non-reducing SDS-PAGE (Figure 2.6A). Densitometry was
performed to determine the GSH adducts compared to amount of protein
(Coomassie, Figure 2.6B). KO + NACA mice had a significantly decreased number
of GSH protein adducts compared to untreated KO mice.
As our lab previously demonstrated that protein succination is associated
with the site of neuropathology as the disease progresses in the Ndufs4 KO model
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(14), NACA was hypothesized to reduce protein succination in the KO mice via the
thiol group directly reacting with fumarate. Figure 2.7 demonstrates a significant
increase in 2SC protein adducts in the KO and KO + NACA mice versus the WT.
NACA treated KO mice did not appear to have a significant reduction in the
concentration of 2SC compared to KO controls. There was no change in the
concentration of HNE protein adducts in the BS of WT mice as opposed to their
KO littermates, signifying that there was not an increase in oxidative stress in the
KO mice.
We used an in vitro model to determine if thiol supplementation could
decrease excess fumarate and the amount of 2SC protein adducts. A fumarase
knock-down (Fh KD) cell line was generated following transduction of N1E-115
neuroblastoma cells with a lentiviral vector containing a fumarase shRNA. These
cells were then differentiated into a neuronal phenotype and the effects on protein
succination and mitochondrial respiration were characterized. The top panel of
Figure 2.8A (2SC) displays the pronounced increase of 2SC in the Fh KD cells
compared to scrambled control (Scr) cells, occurring alongside a significant
decrease in the levels of fumarase protein. Synaptophysin confirms the successful
differentiation of the knock-down cells into neurons (Figure 2.8A). Quantification of
fumarate levels from both Scr and Fh KD cells demonstrated a ~17 fold increase
in Fh KD compared to Scr cells, confirming that the increase in succination was
driven by increased fumarate levels (Figure 2.8B (p<0.001)).
Mitochondrial respiration was assessed in the Fh KD cells to determine the
impact of reduced fumarase protein and increased succination on mitochondrial
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function. Figure 2.9A illustrates that the Fh KD cells had impaired oxygen
consumption versus the Scr control. There were significant decreases in the basal
respiration, ATP production, and maximal respiration in the Fh KD cells versus the
Scr control (Figure 2.9B, (p<0.001)), see Appendix A for a representative
mitochondrial respiratory stress profile). Considering the large increase in
fumarate levels, the Fh KD and Scr control cells were treated with 5 or 10 mM NAC
for 5 days during differentiation in an effort to reduce succination. While 2SC levels
were significantly increased in Fh KD cells compared to Scr control after 5 days,
this was not altered with the addition of NAC at either concentration, suggesting
that fumarate reactivity with NAC thiols is limited (Figure 2.10A) (Scr vs Fh KD, Fh
KD + 5 mM NAC, and Fh KD + 10 mM NAC, Figure 2.10B, (p<0.005)).
While the NACA treated mice had significant improvements in time required
to transverse the balance beam, as well as number of paw slips, this was not
associated with a visible decrease in protein oxidation or succination, nor an
improvement in reduced glutathione levels. Therefore, we hypothesized that early
intervention may be more important to this model, given the severity of the disease
phenotype. Liu et al. treated Ndufs4 KO mice for 7 days with 150 mg/kg/day
beginning at p21, and observed improvement in clinical signs, including a delay of
symptom onset (105). In contrast, we treated the mice for longer (14 days), but did
not initiate NACA treatments until ~p27-32. In order to determine how protein
oxidation is affected, protein sulfenylation was measured via a sulfenic acid
(S-OH) antibody. During oxidative stress, cysteine can undergo a reversible
oxidative modification to S-OH via ROS, including H2O2. Therefore, the level of
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protein S-OH modifications function as a biomarker of redox signaling and
oxidative stress (116, 117). BS and OB were removed from WT and KO mice at
p21 (young) and p45 (old) and placed directly into a dimedone-containing buffer to
stabilize the modification. Figure 2.11A displays a decrease in the amount of SOH present in the BS of old KO mice versus young. Due to the variability in the
densitometry of the bands, while there is not a significant change, the visual
decrease in the sulfenylation of old KO mice versus young (Figure 2.11B).
2.3 Discussion
Both NAC and NACA have been used successfully in several models to
decrease oxidative stress (105-110). NACA offers improved utility over NAC for
the treatment of neurological disorders since it has an improved ability to cross the
blood brain barrier (110).The cysteine of NAC/NACA is a component of the
tripeptide antioxidant, GSH, and we confirmed that NACA treatment in vitro
enhanced the GSH content in neurons responding to DMF induced oxidative
stress, similar to NAC (Figure 2.1A, 2.1C). Our lab has formerly shown that DMF
directly modifies cysteine residues on proteins throughout the treated cells (115).
To date, only one previous study has shown that NACA administration
specifically offers promise for the treatment of MDs (105). NACA administration for
7 days in weaned Ndufs4 KO versus controls reduced the clinical severity of the
disease. This was proposed to be related to the concomitant reduction in
triglyceride accumulation in the VN and OB of the brain, regions in which
triglycerides congregate around the characteristic necrotizing lesions of Leigh
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syndrome (LS). Therefore, lipid droplet accumulation was proposed to be linked to
the early presence of oxidative stress (105).
In the current study, NACA administration for 14 days offered significant
benefit in some behavioral parameters. The performance of the mice on the
inclined balance beam exhibited the most promising results, with significant
differences between the untreated KO and the KO + NACA groups in both the time
to cross the beam and the number of paw slips (Figure 2.3). The success of the
mice on the balance beam following NACA administration demonstrated that this
treatment offered benefit in preserving fine motor control. However, while NACA
had a positive effect on the fine motor skills, it did not increase their speed or
endurance on the rotarod (Figure 2.4). This contrasts with the work of Liu et al.,
who found that the rotarod performance was improved at p30 following 7 days of
NACA administration (105), but did not offer continued benefit at p40 or p60 after
the treatment was stopped. Since our tests were performed at ~p24-28, it is
possible that our studies were not performed within a suitable time frame to see
beneficial effects of NACA treatment on this behavioral parameter. In addition, our
measurements would also benefit from a larger sample size and we plan to
perform further studies to support this. Overall, NACA administration appears to
confer some benefit in preserving motor skills even as the neuropathology
progresses, and should be considered further as an additional treatment to delay
symptoms of LS in patients.
Leigh syndrome has been linked to increased, chronic oxidative stress in
the affected cells (61, 98-100). We hypothesized that reduced glutathione (GSH)
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levels would be lower in the olfactory bulbs of the KO mice, and that NACA
administration might restore or preserve GSH similar to what we had observed in
neurons in vitro (Figure 1A, 1C). We observed a trend for a decrease in GSH
content in KO olfactory bulb versus WT control, as well as an increase in
GSSG:GSH for these groups (figure 2.5). In contrast to our expectations, we
observed a further decrease in GSH levels in the NACA-treated KO mice versus
the untreated KO mice (Figure 2.5A). The ratio of GSSG:GSH was decreased in
NACA treated mice, as were the presence of GSH protein adducts (Figure 2.5B,
2.6), suggesting that NACA conferred some benefit in reducing protein oxidation,
but does not drive large increases in GSH production in the KO mice. NACA
administration did not result in a decreased production of HNE protein adducts in
the brainstem (Figure 2.7); however, these were not detectably increased in the
untreated KO brainstem versus WT, similar to our and other previous observations
(14, 98).
Our lab previously documented that protein succination (2SC) is increased
in the brainstem of KO mice versus WT due to excess fumarate (14). We
hypothesized that the administration of NACA would provide a source of free thiols
that may react with fumarate and preserve protein thiols in the neuronal cells,
offering additional therapeutic benefit. However, there was no difference in the
2SC levels of KO mice versus KO + NACA (Figure 2.7). To further examine if
NAC/NACA would directly reduce protein succination, we employed an in vitro
model using fumarase knock-down (Fh KD) N1E-115 neurons. Fh KD neurons
versus scrambled controls had an ~17 fold increase in fumarate and subsequently
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2SC levels (Figures 2.8). Notably, these cells also had significant decreases in
mitochondrial respiration, as evidenced by decreased basal respiration, ATP
production and maximal respiration (Figure 2.9). When treated with 5 mM and 10
mM NAC for 5 days, there was no reduction in protein succination (Figure 2.10).
Therefore, it is possible that fumarate is not sufficiently reactive with the thiols of
NAC/NACA in vitro and in vivo to provide sufficient protection. Endogenous
fumarate is known to react with low pKa thiols (118), however, the pKa of
NAC/NACA is ~9.6 and 8.5 respectively (119-121). Therefore, NACA may not be
sufficiently reactive with fumarate to provide sufficient protection in this model.
Previous work in fumarase deficient cancer cell lines, where fumarate is elevated
to milimolar levels, did demonstrate some reactivity of fumarate with reduced
glutathione (122, 123), however, the extent of the modification was low and may
only occur when fumarate levels are dramatically elevated.
Ndufs4 KO mice suffer a severe pathology, developing symptoms around
p21 with death occurring at ~p50 (58). Considering that Liu et al. started NACA
treatment at p21 (106), whereas we began treatments at ~p24-28, we
hypothesized that the ~1 week later initiation of treatment may have a large impact
on the ideal window for NACA intervention. In order to test the concept that the
mice must start treatment early to reduce oxidative stress-related pathology, we
used the brainstems of p21 (young) and p46 (old) mice to detect the levels of
sulfenic acid, a product of protein thiol oxidation. We predicted that the younger
KO mice might have increased levels of protein sulfenylation versus the older KO
mice, and Figure 2.11 demonstrates a pronounced difference in several proteins
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in the young and old KO mice, with substantial decreases in select protein in the
older mice. This suggests that increased protein oxidation occurs early in the
brainstem of the Ndufs4 KO mouse, and may be contributing to the neuropathology
that these mice develop, even if changes in oxidative stress markers e.g. HNE
cannot be detected later. Therefore, our results suggest that NACA intervention in
the Ndufs4 KO model of Leigh Syndrome will offer maximal benefit if administered
early and for longer periods across the mouse lifespan. This also emphasizes the
importance of early confirmed diagnosis in human patients so that advantageous
therapeutic strategies can be prescribed earlier in the course of the disease.
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Figure 2.1 Glutathione Fluorescence Assay performed on neuronal cells
treated with DMF, NAC, and NACA. A,C) Amount of reduced glutathione in
neuronal cells normalized to protein content. B,D) Amount of oxidized glutathione
normalized to protein content. A and B were treated with 5 mM NAC for 24 hours
followed by 100 µM DMF for an additional 5 hours. C and D were treated with 5mM
NACA for 24 hours with a further treatment of 100µM DMF for 5 hours prior to
scraping (DMF n=5, Control, NAC, NACA, NAC + DMF and NACA + DMF n=6,
***p<0.001 compared to DMF; statistics via one-way ANOVA, SEM.).
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Figure 2.2 Body weight of mice. Average body weight of the mice in each
experimental group, where week 0 is the weight at the beginning of testing, and
the final weight (week 3) was measured prior to the termination of the study (WT
n=11, WT + NACA n=4, KO n=7 and KO + NACA n=7, SD).
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Figure 2.3 Balance beam testing performed on wild-type (WT) and knock-out
(KO) mice before and after NACA injections. A) The average amount of time
taken for mice (by treatment group) to cross the inclined balance beam before and
after drug administration (***p<0.001 vs pre KO). B) Average period of time for
mice to transverse beam after treatment (*p<0.05 vs WT, **p<0.01 vs WT, #p<0.05
vs KO). C) Number of paw slips by each treatment group during one run across
the inclined beam after NACA or saline treatments (*p<0.05 vs WT, **p<0.01 vs
WT, ### p<0.001 vs WT; n=11, 4, 7 and 6 for WT, WT + NACA, KO and KO +
NACA respectively; statistics via two-way ANOVA, SEM.).
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Figure 2.4 Rotarod testing performed on NACA injected mice. A) The average
amount of time for the mice to fall from the rotarod before and after drug
administration (maximum of 300 seconds) (**p<0.01 for pre of same treatment
group). B) The final times for mice to fall, averaged by their treatment group (*
p<0.05 vs WT, **p<0.01 vs WT; n=11, 4, 7 and 7 for WT, WT + NACA, KO and KO
+ NACA respectively; statistics via two-way ANOVA, SEM.)
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Figure 2.5 Glutathione Fluorescence Assay of olfactory bulbs following
NACA treatment. A) Reduced glutathione concentration in the OB of Ndufs4 mice
normalized to protein content (*p<0.05 compared to KO mice). B) The ratio of
oxidized (GSSG) to reduced GSH (statistics performed via one-way ANOVA. WT
n=8, KO n=5, and KO + NACA n=6, SEM).
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Figure 2.6 Glutathione analysis of mouse brainstem following treatment.
A) 40 µg of protein from the BS was run on a gel under non-reducing conditions
and probed with the GSH primary antibody (top panel). Coomassie displays
loading of the protein (bottom panel). B) Densitometry analysis, via Image J
software, of the GSH adducts normalized to the Coomassie; demonstrating
normalization to protein content (*p<0.05 compared to KO mice, statistics
performed via one-way ANOVA, SEM.).
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Figure 2.7 Protein analysis of brainstem from mice after NACA. 30 µg of BS
protein run via SDS-PAGE. The top blot, 2SC, presents the intensity of the
modification, in a multitude of proteins, as it increases in Ndufs4 KO mice versus
WT, without exhibiting a change between KO and KO + NACA BS samples. HNE
displays no significant change between the groups (HNE panel). The Coomassie
denotes equal loading of BS protein.
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Figure 2.8 Effects of Fh knock-down (KD) on protein succination, neuronal
differentiation, and intracellular fumarate concentration. A) 20 µg protein from
scrambled (Scr) and Fh KD N1E-115 differentiated cells probed with anti-2SC
(2SC panel). Increased succination is observed for a large number of proteins in
the Fh KD cells. Confirmation of the fumarase shRNA effectiveness to decrease
fumarase expression is also shown (fumarase panel). Differentiation of the cells to
a neuronal phenotype was confirmed by the expression of the presynaptic marker
synaptophysin (synaptophysin panel). Even loading of the lanes was confirmed by
Coomassie staining (Coomassie panel). B) Fumarate concentration in extracts
from Fh KD is increased more than 17-fold compared to Scr N1E-115 cells. (n=5,
***p<0.001 vs Scr control, SD).

39

A

Rot +
FCCP Ant

OCR (pmol/min/ug protein)

Oligomycin

OCR (pmol/min/ug protein)

B

Figure 2.9 Effects of Fh knock-down on mitochondrial respiration.
A) Respiratory profile of Fh KD and Scr N1E-115 neurons measured using the
Seahorse XF analyzer. Compounds were added at the indicated arrows to assess
mitochondrial function (**p<0.01 vs Scr). B) Basal respiration, proton leak, oxygen
consumption coupled to ATP production, maximal respiration, spare capacity, and
non-mitochondrial respiration were calculated following the addition of oligomycin,
FCCP, and rotenone/antimycin A (Rot + Ant), (**p < 0.01 vs. Scr control, n=5,
SD) (See Appendix A for determination of respiratory profile).
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Figure 2.10 2SC levels of fumarase knock-down cells treated with NAC. A) 30
µg of protein from Fh KD and Scr N1E-115 cells treated with 5 mM and 10 mM
NAC was probed with anti-2SC, demonstrating increased succination in the KD
cells. Coomassie panel presents protein loading. B) 2SC levels were normalized
to Coomassie via Image J and graphed with Sigma Plot. This demonstrated
significantly increased succination in Fh KD cells, compared to Scr, but no
significant change when cells were treated with NAC compared to control
(**p<0.01 equated to Scr control, statistics performed via one-way ANOVA,
SEM).
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Figure 2.11 Detection of protein sulfenylation in the brainstems of young and
old wild-type and knock-out mice. A) 20 µg of protein from the BS of young and
old WT and KO mice run via SDS-PAGE, and probed with anti-S-OH. Actin exhibits
protein loading (actin panel). B) S-OH content normalized to actin via densitometry
performed on Image J. While there were no significant decreases due to the
variability in band intensity, there was a pronounced trend for decreased
sulfenlyation in old KO mice versus young ( SEM).
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CHAPTER III
MICROGLIAL DEPLETION IN A MOUSE MODEL OF LEIGH
SYNDROME
3.1 Introduction
Microglia are the principal immune cells of the central nervous system
(CNS), and compose approximately 12% of the total cells in the CNS (124).
Microglia play a crucial role in limiting damage from injury, for example,
phagocytosing aggregating peptides that may be toxic and limiting plaque
formation (124-126). In other situations, however, this “beneficial” response may
lead to chronic inflammation in the brain, contributing further to the disease (124,
127). During neuroinflammation, the microglia secrete proinflammatory cytokines,
including IL-1β, IL-6 and TNFα that may exacerbate neuronal damage or injury
(128, 129). Rice et al. induced lesions in the brain of mice and discovered that
activated microglia increased the level of inflammation, which was associated with
impeded recovery. Once lesions were present, removal of the microglia resulted
in improved scores on the elevated plus maze, in addition to reversing the lesioninduced pro-inflammatory release, including B2m and Bax. While microglia prove
beneficial during a diphtheria toxin-induced neuronal lesion, their continued
presence also correlated with delayed recovery post-lesion (127).
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Colony stimulating factor 1 receptor (CSF1R) is a cell surface receptor
located on macrophages, microglia and osteoclasts (130). CSF1, a natural ligand
of the CSF1R, is a growth factor that regulates the proliferation, differentiation, and
survival of these cell types. Microglia are the only cells in the brain that express
CSF1R, and CSF1R knock-out mice are devoid of microglia in the brain (130, 131).
Recently, a pharmacological approach was developed that specifically depletes
microglia via inhibition of CSF1R signaling (131, 132). Spangenberg et al.
eliminated approximately 80% of the microglia in a mouse model of Alzheimer’s
disease using a CSF1R inhibitor, resulting in the rescue of dendritic spine loss,
preventing neuronal loss, reducing neuroinflammation, and improving contextual
memory (133). CSF1R inhibitors have also been used to improve radiationinduced cognitive deficits in mice treated with irradiation for brain cancer (134).
PLX5622 (PLX) is a CSF1R inhibitor proven to eliminate up to ~99% of
microglia in the nervous system of mice receiving it orally over several days to
months (124, 135). Acharya et al. treated mice for 3 days with 1200 mg/kg of PLX,
resulting in 95% reduction in microglial number (134). A lower concentration of 300
mg/kg was fed to 3xTg-AD mice, a model of Alzheimer’s disease, for 7-21 days
and resulted in a 30% reduction of microglial number and improved cognition
(124). Results were obtained using C57BL/6J, a common black laboratory mouse,
discovering that both the 300 mg/kg and 1200 mg/kg doses of PLX achieved
comparable microglial reductions (136). Ndufs4 KO mice have been observed with
enhanced microglial activation, particularly in regions suffering from necrotizing
lesions. As the gliosis and lesions worsen, the ataxia, hypothermia, and morbidity
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increase simultaneously (59). Ionized calcium binding adaptor molecule 1 (Iba-1)
is a protein expressed solely in microglia, regulating their function (137, 138). We
hypothesized that PLX administration to deplete microglia and reduce
neuroinflammation in the Ndufs4 KO mice may reduce microgliosis and the motor
co-ordination deficits associated with the neuropathology. In addition, we have
recently observed that activated macrophages (lipopolysaccharide-stimulated)
have pronounced increases in fumarate and protein succination (unpublished
data). Therefore, we hypothesized that PLX-mediated removal of microglia (the
macrophages of the CNS) may result in a decrease of protein succination in the
KO mice. Alternatively, it may increase neuronal survival and also prevent
increased succination in neuronal cells. Thus, we investigated diets containing
both the 300 mg/kg (low dose) and 1200 mg/kg PLX (high dose).
3.2 Results
PLX5622 (PLX) is a CSF1R inhibitor demonstrated to eliminate microglia
(124, 134-136), and these experiments represent the first use of this compound in
a mitochondrial disease model to decrease neuroinflammation. In this study, two
trials were performed, one using 1200 mg/kg PLX in the diet for 3 days, and the
other with 300 mg/kg PLX for 14 days. Previous work has been conducted in
murine models for a duration of 1-3 months, however, shorter exposures (up to 2
weeks) are necessary in the Ndufs4 KO model as they have such a severe disease
progression and die by <9 weeks of age (124, 136, 139).
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A specific anti-Iba-1 was used for immunoblotting to assess the levels of
Iba-1 in both the brainstem (BS) and olfactory bulb (OB) of WT and KO mice
(Figure 3.1A). While there was a slight increase in Iba-1 concentration in BS from
WT mice versus KO, the OB demonstrated a significant increase in Iba-1 in the
KO mice versus their WT littermates, confirming the microgliosis. To determine,
more specifically, if the mice would be treated at an age where KOs already
contained increased microglia, early (p24-26) and mid (p46) KO mice OB were
compared to early (p24-26) and late (p60-63) WT mice OB. Iba-1 probing
demonstrated a significant difference in both of the KO age groups versus the WT
controls (WT early versus KO early and mid (p<0.05); WT late versus KO early
and mid (p<0.001), Figure 3.1 B, 3.1C), confirming that microgliosis is present as
early as p24 in the KO mice.
Mice were to be treated with PLX for 3 days (1200 mg/kg) or 14 days (300
mg/kg) beginning at approximately p22-24. When administered the 1200 mg/kg
dose, Ndufs4 KO mice suffered rapidly declining health, including respiratory
distress and limited-to-no motor movement. This lead to termination of the study
at three days and the determination that Ndufs4 KO’s pathology is too severe to
survive on the 1200 mg/kg dose of PLX. The 14 day, 300 mg/kg PLX trial also
triggered a worsening in clinical symptoms, leading to an early cessation of the
experiment. A PLX-treated mouse died 2 days prior to the planned termination of
the study (14 days), and resulted in the early termination of the study at 13 days.
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Following the PLX treatment of the WT and KO mice, the BS of the 3 day
(1200 mg/kg diet) and 13 day (300 mg/kg diet) were examined to determine if Iba1 levels had been altered by either treatment (Figure 3.2A). While several bands
were apparent on the Iba-1 blot, the band ~17kDa appeared to be more intense in
the untreated WT group versus the KO mice, which is inconsistent with our
previous observations in Figure 3.1, and the work of others (44). PLX treatment of
the WT mice appeared to significantly decrease Iba-1 levels (Figure 3.2B,
p<0.001). However, since the levels of Iba-1 could not be accurately assessed in
the whole brainstem across all groups, despite multiple attempts, we could not use
this to determine if PLX treatment had been successful in these mice.
Unfortunately, the olfactory bulbs from these mice were used for a separate
experiment and were not available for protein analysis.
Due to the fact that activated microglia may show increased fumarate levels
and protein succination, we hypothesized that decreasing the heightened
population of microglia in KO mice would decrease the levels of 2SC present.
Figure 3.3A displays the levels of 2SC in the BS of mice from the 3 day PLX study.
There was no significant difference in untreated KO mice, and those receiving PLX
(Figure 3.3B). BS protein was also immunoblotted and probed with anti-2SC for
the 13 day treated mice (Figure 3.4A). As expected, 2SC levels were again
increased in the untreated KO versus WT (p<0.01), however there was no
significant change in 2SC levels between treated and untreated KO groups (Figure
3.4B). Note: one of the PLX treated Ndufs4 KO mice was included on the blot and
appeared to have reduced succination (lane 9, Figure 3.4A). However, was
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subsequently learned that this mouse had died prematurely and had been
refrigerated prior to protein calculation. This lane was not included in normalization
or statistical analysis. Overall, the data suggested that 2SC levels were not
significantly altered in the PLX treated KO mice versus untreated KO; however,
the sample size of remaining mice in the study was limited.
Since the mice did not have any improved survival on the 300 mg/kg PLX
containing diet for 14 days, we performed a trial on WT mice in order to determine
a shorter period of time that would still significantly reduce the amount of microglia.
WT mice were given 300 mg/kg PLX chow for 3, 5, or 7 days, and the hippocampus
was used for Iba-1 probing. The hippocampus was selected as this region exhibits
a change in microglial content when mice are fed PLX (124). Hippocampal Iba-1
levels showed significant reduction for 3, 5 and 7 days (control versus 3, 5 and 7
day PLX, Figure 3.5A, 3.5B, (p<0.001)). While all three treatments times displayed
reductions in Iba-1, we decided to perform a 7 day treatment with PLX, as it
demonstrated the greatest change from the control mice.
Since we observed negative effects on the mice when we attempted to
remove all of the microglia over 13 days, we hypothesized that a minimal period of
7 days on PLX, followed by another 7 days for repopulation, would be more
beneficial for the KO mice. We considered that repopulation of the affected area
with healthy microglia might prove beneficial for the removal of dying neurons in
the Ndufs4 KO model, and that the microgliosis that is present may be the result
of an impaired ability for microglial turnover.
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Behavioral tests were performed the prior to PLX administration (day 0),
after PLX administration (day 6-7), and finally after repopulation (day 12-13). The
rotarod was used to assess the speed and endurance of the mice, in addition, we
considered time spent “cart-wheeling”, in which the mice are not continually
running on the wheel, but holding-on and allowing the wheel to spin them around,
thereby breaking from the exercise. The time that the mice were able to run on the
wheel was recorded, minus time spent cartwheeling. Figure 3.6A displays an
average time for the treatment groups during each testing cycle. The WT + PLX
mice had a subtle decrease in time spent on the rotarod directly after drug
administration, but were able to run longer after the repopulation period. During
the repopulation period, there was a significant decrease in time to fall between
WT mice versus KO and KO + PLX (WT vs KO and KO + PLX, Figure 3.6B, 3.6C,
3.6D, (p<0.01)). There were no statistical significances discovered between KO
and KO + PLX mice at any time point tested.
An inclined balance beam was used to test the speed and fine motor
coordination of the mice. The time for mice to transverse the meter-long beam was
recorded, along with the number of paw slips during the test. There was a
significant increase in the time to cross for WT + PLX following PLX administration
(p<0.05) and after repopulation (p<0.01) (Figure 3.7 A, C, and D). There were
significant differences between WT mice and both KO and KO + PLX directly after
treatment (WT vs KO and KO + PLX, Figure 3.7B, (p<0.05)). WT versus KO mice
had a p-value of <0.05, while WT versus KO + PLX had slightly greater significance

49

with p<0.01. However, no statistical significance was found between KO and KO
+ PLX, following the repopulation period.
Paw slips were difficult to determine during the repopulation period due to
two mice not being able to keep their paws on the top of the beam, therefore only
one mouse in the KO group and two in KO + PLX could be considered. Figure 3.8A
demonstrates a continually increasing number of paw slips in the KO + PLX group,
while the other treatment groups are significantly lower. There was an increase in
paw slips in the KO + PLX immediately post-treatment versus prior to treatment
(KO + PLX pre vs post, Figure 3.8C, (p<0.05)). The number of paw slips in the
testing period after microglial repopulation was significantly increased over both
pre-treatment and post-treatment (pre vs repopulation (p<0.001), post vs
repopulation (p<0.05), Figure 3.8C). Immediately after the 7 day treatment, KO +
PLX had a significantly increased number of paw slips in comparison to WT mice
(WT vs KO + PLX, Figure 3.8B, (p<0.05). The difference between KO + PLX and
WT was increased further after repopulation, as well as a significant difference
between KO and KO + PLX (WT vs KO + PLX (p<0.001), KO vs KO + PLX
(p<0.05), Figure 3.8B, 3.8D). The data suggested that the number of paw slips
increased following PLX treatment in the KO mice, but not in WT animals, although
the limited sample size is a source of variability in these measurements.
Ndufs4 KO mice are naturally smaller and weigh less than their WT
counterparts. WT and WT + PLX mice had significantly increased body weight from
day 0 (beginning of PLX) until day 14 (sacrifice) (WT day 0 vs day 14 (p<0.01), WT
+ PLX day 0 vs day 14 (p<0.01), Figure 3.9A), while KO and KO + PLX mice did
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not show significance. During the last four days of the study (day 11 to 14), KO
and KO + PLX mice both displayed weight that was significantly lower than their
WT counterparts (Figure 3.9B). KO + PLX mice weighed less than control KO mice,
and showed a greater significance compared to both WT groups.
Protein analysis was completed on the olfactory bulb of the mice, probing
for both 2SC and Iba-1. Probing for microglial marker content in the OB with Iba-1
showed, that while there was a slight increase in KO + PLX mice versus KO, there
was no significance (Figure 3.10A, 3.10B). This confirmed that microglial
repopulation occurred, however, the limited number of mice in the study prevented
a post-treatment analysis of Iba-1 at 7 days. Anti-2SC immunoblotting displayed a
significant increase in KO and KO + PLX mice compared to WT mice (WT vs KO
and KO + PLX, Figure 3.10C, 3.10D, (p<0.001). However, there was no difference
between KO and KO + PLX, suggesting that treatment did not alter succination
levels in the newly repopulated microglia.
3.3 Discussion
PLX treatment has been shown to remove up to ~99% of microglia following
a 21 day exposure in dietary chow (136). In this study we first confirmed increased
microgliosis in the olfactory bulbs of KO versus WT mice (Figure 3.1), however,
Iba-1 levels could not be reliably detected with the antibody in the brainstems of
the 3 day and 13 day PLX treated mice (Figure 3.2). Unfortunately, the olfactory
bulbs were not available for Iba-1 analysis in these mice, as this region appears to
be more reliable for the detection and monitoring of microgliosis. Nevertheless,
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while we could not reliably confirm that the drug had resulted in microglial
clearance, it was evident that the microglial removal did not confer any additional
benefit on survival of the KO mice as there was a steep decline in the severity of
clinical symptoms. The 3 day treated mice had respiratory difficulties, highly
impaired motor coordination and muscle strength, resulting in the necessity of
chow being placed beside the mice, as they were not able to feed otherwise. While
Ndufs4 KO mice treated for 13 days were slightly healthier than those receiving
PLX for 3 days, their condition was significantly harsher than that of untreated
mice, ultimately resulting in premature death of one mouse. For this reason the
planned 14 day PLX intervention had to be terminated early at 13 days.
Despite the apparent lack of benefit, we were still interested to determine if
microglial removal had resulted in altered succination profile in the brain. A recent
collaboration with another laboratory highlighted that activated macrophages may
have increased levels of protein succination in the brain during neuropathology in
the KO mice. To determine if PLX administration and microglial removal reduced
succination, we performed immunoblotting for 2SC in the 3 day and 13 day treated
mice (Figures 3.3 and 3.4). There was a trend for a slight reduction in protein
succination in the PLX treated KO mice versus untreated KO, however, it is difficult
to determine if this was due to a limited effect of PLX to remove microglia, or if
succination was significantly altered. It is possible that the (dying) neurons contain
higher levels of succinated proteins and therefore a decrease in the microglia may
not be detectable in the affected brain region. The trend for a decrease does

52

warrant further investigation in a study where reduced microglial content can be
confirmed.
Since 14 days on PLX was confirmed to be too long a period for our mice,
a time course was set up to discover if administration for 3, 5, or 7 days would be
a better alternative. Using the promising elimination data obtained in Figure 3.5,
we further hypothesized that administration of PLX for 7 days, followed by allowing
7 days for ‘new’ microglial repopulation would be a better strategy. This would
remove the unhealthy microglia that they have difficulty being cleared from the
lesion, and allow new, healthy microglia to surround the lesion and help
phagocytose the neuronal debris. We anticipated that this would result in a slightly
decreased number of microglia in KO + PLX versus KO control mice, and hoped
to see increased motor coordination during behavioral tests if survival was
positively impacted.
The test of speed and endurance, rotarod, demonstrateded the KO and KO
+ PLX mice had approximately identical performance through the three testing
periods. Both untreated and treated KO mice fell from the rotarod earlier in each
subsequent testing period (Figure 3.6). Balance beam also measured speed, as
well as fine motor coordination reflected similar results, with both taking longer to
transverse the beam (Figure 3.7). The PLX treated KO mice appeared to have
more paw slips (Figure 3.8), however, there was a lot of variability in this
measurement and we were severely hindered by the small sample size in the
experiment. These studies will need to be repeated with a much larger sample
size.
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Protein analysis of the 7 day on/7 day off PLX mice was performed to
determine Iba-1 levels in the brain after the treatment. Unfortunately, we did not
have sufficient mice to sacrifice a separate group at 7 days, immediately after the
drug had been administered as we hoped to record more positive behavioral
changes and focused on this with this particular group of mice. Iba-1 displayed an
increase in microglia of KO + PLX versus KO mice, although this was not
significant (Figure 3.10). Elmore et al. also experimented with withdrawal of PLX
and showed microglia exhibiting a larger morphology versus control at 3 and 7
days post-PLX. They also displayed a higher concentration of microglia at 7 days
after treatment, while by 14 days, the population of microglia was almost normal
(130). Both increased size and number of microglia could explain the increase in
Iba-1 we observed, as well as 2SC levels remaining unchanged between the
untreated KO and KO + PLX groups. We proposed that the KO + PLX KO mice
would contain fewer succinated proteins because the unhealthy microglia would
be absent, along with their heightened level of succination. However, the increased
number of microglia may result in a relatively unchanged amount of protein
succination, even if the level of succination in individual cells is decreased.
Overall, these preliminary studies with PLX demonstrate that profound
decreases in microglial number do not appear to positively impact behavior or
survival in the Ndufs4 KO model similar to studies in other disease models. This
may be related to the severity of the neuropathology in the Ndufs4 KO mice, and
the fact that the microglia are performing a necessary function to remove dying
neurons in the affected brain regions of these mice.
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Figure 3.1. Brainstem versus olfactory bulb and effects of aging on
microglial concentration. A) Trial of brainstem (BS) vs olfactory bulb (OB) used
40 µg protein from respective areas to display differences in Iba-1 between WT
and KO mice. B) Effects of aging on Iba-1 levels in 40 µg of protein from OB (WT
early (p24-26), KO early (p24-26), KO mid (p46) and WT late (p60-63)). C)
Normalization of age Iba-1 blot to Coomassie (*p<0.05 vs WT early; ###p<0.001
vs WT late. Statistics performed via one-way ANOVA, SEM).
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Figure 3.2 Microglial concentration in mice treated with PLX for 3 and 13
days. A) 40 µg BS protein, run using SDS-PAGE and probed for Iba-1 for WT and
KO mice treated with PLX for 3 and 13 days (middle band, 17kDa) (lanes 1-5 =
untreated WT, lanes 6-9 = WT + 3 day PLX, lanes 10-12 = WT + 13 day PLX, lanes
13-15 = KO + 13 day PLX, lanes 16-19 = KO + 3 day PLX, lanes 20-23 = untreated
KO). B) Iba-1 of 3 versus 13 day PLX normalized to Coomassie (**p<0.01 vs WT;
***p<0.001 vs WT; ##p<0.01 vs WT-3; WT n = 5, WT-3 n = 4, WT-13 n = 3, KO–
13 n = 3, KO-3 n = 4, KO n = 4; Statistics performed via one-way ANOVA, SEM).
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Figure 3.3 Differences in succination of the brainstem with 3 day PLX
treatment. A) 30 µg BS protein from 3 day PLX treated mice was probed with anti2SC. B) Normalized 2SC levels to Coomassie (***p<0.001 vs WT; WT n = 2, KO
n = 2, KO + 3 day PLX n = 4, WT + 3 day PLX n = 4; Statistics performed via oneway ANOVA, SEM).
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Figure 3.4 Determination of 2SC content in the brainstem of 13 day treated
PLX mice. A) 40 µg protein was run via SDS-PAGE, and probed with 2SC
antibody (+ is positive control, Fh KD cell protein). B) Densitometry performed on
2SC with Image J and normalized to Coomassie (*p<0.05; **p<0.01. Statistics via
one-way ANOVA,
SEM). *The third lane in KO + PLX was not used for
normalization or statistics, as this mouse died prior to the others, and was not
dissected and frozen immediately, the carcass was first refrigerated for several
hours.
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Figure 3.5 Test for the efficiency of PLX in eliminating microglia over 3, 5,
and 7 days. A) 40 µg protein from the hippocampus of WT mice treated with PLX
for increasing variables of time was probed with anti-Iba-1 to test for microglial
presence. B) Normalized amount of hippocampal Iba-1 to Coomassie (***p<0.001
vs control, SEM).
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Figure 3.6 Rotarod testing of mice treated with PLX for 7 days followed by a
7 day repopulation period. A and B) Average time to fall for mice during pre,
post and repopulation periods (**p<0.01 vs WT repopulation). C) Average time to
fall for each treatment group at the 3 time points. D) Average time for mice to fall
after the 7 day repopulation period (**p<0.001 vs WT, WT n = 4, WT + PLX n = 4,
KO n = 2, KO + PLX n = 3; statistics calculation via two-way ANOVA, SEM).
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Figure 3.7 Balance beam behavioral testing for mice treated with PLX 7 days
on and 7 days off. A and B) Average times of treatment groups for pre-, postand repopulation periods (*p<0.05 vs WT post-treatment; #p<0.05 vs WT
repopulation; ##p<0.01 vs WT repopulation). C) Average time to converse the
beam of each treatment group, at the three testing stages (*p<0.05 vs KO + PLX
pre; **p<0.01 vs KO + PLX pre). D) Time for the groups to cross the beam during
the final repopulation testing (*p<0.05 vs WT; **p<0.001 vs WT, WT n = 4, WT +
PLX n = 4, KO n = 2, KO + PLX n = 3; statistics performed in Sigma Plot via twoway ANOVA, SEM).
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Figure 3.8 Paw slips of mice while crossing the balance beam. A and B)
Average number of paw slips during each testing period (#p<0.05 vs WT post;
***p<0.001 vs WT repopulation; $p<0.05 vs KO repopulation). C) Average paw
slips for treatment groups during the 3 tests (*p<0.05 vs KO + PLX pre; ***p<0.001
vs KO + PLX pre; #p<0.05 vs KO + PLX post). D) Paw slips during repopulation
testing (***p<0.001 vs WT; #p<0.05 vs KO, WT n = 4, WT + PLX n = 4, KO n = 1,
KO + PLX n = 2; statistics via two-way ANOVA, SEM).
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Figure 3.9 Weight of mice from initial treatment exposure (Day 0) to date of
sacrifice (Day 14). A) Body weight of mice (**p<0.01 vs WT Day 0; ##p<0.01 vs
WT + PLX Day 0) B) Body weight of mice by individual date (#p<0.05 vs WT +
PLX; *p<0.05 vs WT; **p<0.01 vs WT; ***p<0.001 vs WT). (WT n = 4; WT + PLX
n = 4; KO n = 2; KO + PLX n = 4; statistics via two-way ANOVA, SD).
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Figure 3.10 Protein analysis of olfactory bulb samples obtained from 7 day
PLX, 7 day repopulation mice. A) 40 µg OB protein was loaded and run with
SDS-PAGE and probed with Iba-1 antibody. B) Iba-1 blot normalized to
Coomassie using Image J software. C) 30 µg protein was loaded and probed with
2SC using Coomassie for protein loading control D) 2SC blot normalized to
Coomassie via Image J (**p<0.01 vs WT; ***p<0.001 vs WT; statistics performed
via one-way ANOVA, SEM).
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CHAPTER IV
FUTURE DIRECTIONS
Due to the visual difference in sulfenylation of KO young versus old mice, I
believe that it would be good to begin administering NACA at 21 days, as
performed in Liu et al. We would continue to treat for the full 14 days in an effort to
enhance the results that they observed, including a delay in the onset of
symptoms, as well as decreasing their severity. Since we believe that the oxidative
stress begins early in life, and does not seem as predominant later, treating this
early could potentially increase the longevity of the mice, as well as their standard
of living.
We proved that there was a significant decrease in the number of microglia
when WT mice were treated with PLX for 7 days, thereby predicting that a 7 day
period after this would allow new, healthier microglia to repopulate and assist the
brain. The next experiment would build on the 7 days on/7 days off experiment we
already completed. More mice would be used in order to obtain additional testing
groups, as well as adding to the data from the current mice. These groups would
include mice both sacrificed directly after the 7 day treatment period and pushed
to survive an additional 7 days past the current repopulation period. Protein
analysis immediately following microglial elimination would allow us to determine
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the proficiency of PLX5622 in this mouse model. In addition, 2SC levels, from all
four time points, would be measured to determine if the new microglia are
‘healthier’ in terms of succination. Besides the protein analysis, we would take
slices of the BS, particularly the VN, and the hippocampus. Immunohistochemistry
of sections from before PLX treatment, immediately post-treatment, after 7 days
repopulation, and 14 days repopulation would allow us a visual of the number and
size of microglia present, when staining with Iba-1. While immunoblotting allows
us to see the amount of certain proteins, this will allow visualization of where they
are located and if size or shape has changed due to the treatment. That way we
would be able to determine if results observed in Elmore et al. (126) apply to our
mice as well, with altered size and cell count throughout the repopulation period.
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MATERIALS AND METHODS
Materials. Unless otherwise noted, all chemicals were purchased from Sigma
Aldrich (St. Louis, MO). Anti-2SC antibody was prepared by Eurogentec (Fremont,
CA). Tween-20 and Criterion™ TGX™ Precast Gels were from Bio-Rad (Hercules,
CA). Polyvinylidene fluoride (PVDF) was purchased from GE Healthcare (Fairfield,
CT). L-glycine and sodium dodecyl sulfate (SDS) were purchased from Fisher
Scientific (Waltham, MA). N-acetylcysteine amide (NACA, (R)-2-Acetamido-3mercaptopropanamide) was synthesized by Matrix Scientific (Columbia, SC).
PLX5622 was generously provided by Plexikkon Inc. in standard chow prepared
by Research Diets Inc. (Berkeley, CA) (300 mg/kg D11100406i) (1200 mg/kg
D11100404i).
Animal Model. All animal use described in this and other sections was consistent
with the guidelines issued by the National Institutes of Health and were approved
by the University of South Carolina Institutional Animal Care and Use Committee.
NDUFS4 knock-out mice were obtained from Dr. Richard Palmiter (University of
Washington, WA). The mice were bred and pups were genotyped at 3 weeks. WT
and KO mice in the NACA experiment were treated with intraperitoneal injections
of 150mg/kg/day NACA for 14 days, beginning at approximately p26. At the
termination of the studies mice were anesthetized by isoflurane prior to
decapitation. In the PLX experiment, Ndufs4 KO mice were treated with 1200
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mg/kg PLX for 3 days or 300 mg/kg PLX for 7 or 13 days. The mice participating
in the 7 day on/7 day off PLX study underwent behavioral testing prior to 7 days of
300 mg/kg PLX, followed by a 7 day repopulation period before being anesthetized
by isoflurane, followed by decapitation.
Behavioral Testing
Balance Beam. Mice underwent training 3 days prior to testing, as well as
habituation 30-60 minutes before the test. Mice were placed at the end of a
one meter long beam with a width of 7 mm. The beam was placed at a 4
degree angle with a black box at the opposite end containing food and
bedding. The mouse was allowed 20 seconds to sit in the box before
crossing the beam. Between trials, mice were allowed an additional 15-20
seconds to recuperate in the box. Total number of paw slips and the time
taken to cross were both measured during the 4 times the mouse crossed
the beam. The three best times were used for statistics.
Rotarod. As stated above, mice were trained 3 days before testing, and
habituated in the room. The speed on the rotarod was increase 4-40 rpm
over a span of 5 minutes. Mice were tested 5 times each, with four of those
used for statistics. In PLX experiment, mice were recorded, and
cartwheeling time taken into account. Cartwheeling occurs when the mouse
holds onto the wheel and circles instead of running.
Protein Extraction from Brain Tissue. Brainstem, olfactory bulb, or hippocampus
were added to 100-250 µL radio immunoprecipitation assay (RIPA) buffer along
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with 2 mM Sodium Fluoride, 2 mM Sodium Orthovanadate, and 1/1000 protease
inhibitor cocktail (RIPA+ buffer) and sonicated 2 times for 7 seconds each. The
tissue was incubated on ice for 10 minutes and centrifuged at 5000 rpm for 10
minutes at 4°C. A supernatant and pellet were then visible. The supernatant was
extracted and acetone (9x volume) was then added to each supernatant sample.
The samples were vortexed, allowed to sit on ice for 10 minutes and then
centrifuged at 2000 rpm for 10 minutes at 4°C. The acetone was removed
completely and the protein pellets were re-suspended in 125-200 µL of RIPA+
buffer and sonicated for 10 seconds each. The protein concentration was
determined using the Lowry method (140).
Cell Culture and Viral Transduction. The lentiviral vectors were prepared by the
University of South Carolina Viral Vector Facility. Briefly, TRC2 Fh1 shRNA, cloneTRCN0000246831 or SHC202 MISSION TRC2 pLKO.5-puro Non-Mammalian
shRNA control plasmids (Sigma/Aldrich) were used to generate the lentiviral
vectors. The specific vector plasmid packing, envelope and Rev plasmids were
transfected into 293T cells. N1E-115 neuroblastoma cells obtained from Sigma
were grown in 90% DMEM plus 10% fetal bovine serum (non-differentiation
medium). At 80% confluence, the cells were washed with DPBS prior to the
addition of the lentiviral vectors for transduction. Selection of transduced cells with
puromycin (1.75 g/ml) started 2 days later and lasted for 1 week. At the end of this
period, the remaining cells were expanded and differentiated into neurons in the
presence of 2% FBS, 1.25% DMSO in DMEM in addition to 1 g/ml puromycin for
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5 days. The cells were harvested in RIPA buffer; protein extracts were subjected
to immunoblotting
Primary Neuron Isolation and Culture. Primary neurons from newborn mouse
brain cortices were isolated and cultured using an adaptation of the method
described by Brewer (141). Briefly, postnatal day 1 mice were sacrificed by
decapitation, the brains were aseptically dissected and cortices were separated
from the rest of the brain in ice-cold Hibernate A medium (Gibco/Thermo Fisher
Scientific, Waltham, MA), containing 2% (v/v) B-27 supplement (Gibco/Thermo
Fisher Scientific) and 0.5 mM glutamine (Invitrogen/Thermo Fisher Scientific,
Waltham, MA). The tissue was minced in fragments of about 1 mm3 with a scalpel,
and subjected to digestion with 2 mg/ml papain (Worthington Biochemical Corp.,
Lakewood, NJ) in the supplemented Hibernate A medium for 20 min at 30°C in a
shaker incubator set at 100 rpm. After thorough trituration through a fire polished
Pasteur pipette, the tissue was allowed to settle for 5 min and the supernatant was
carefully layered on top of a discontinuous OptiPrep (Sigma-Aldrich) gradient
prepared in Hibernate A medium; the layers contained 35, 25, 20 and 15%
OptiPrep. The gradient was centrifuged at 800 g for 15 min at room temperature,
and layers 1 (15% OptiPrep) 8 and 2 (20%) were discarded. Layer 3 (25%) was
collected and added a five-fold volume of Neurobasal A medium (Gibco/Thermo
Fisher Scientific), containing 0.5 mM glutamine and 2% B-27 supplement. After a
centrifugation at 500 g for 5 min, cells were resuspended in Neurobasal A medium
containing 0.5 mM glutamine, 2% B-27 supplement, and 5 ng/ml bFGF
(Invitrogen/Thermo Fisher Scientific); counted and plated on 24-well plates
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pretreated with 0.01% poly-L-lysine (Sigma-Aldrich) at a density of 200,000
cells/well. Fifty percent of the media was replaced every third day, with the addition
of 5 µM AraC from DIV 3 to inhibit glial proliferation. On DIV 8, cells were left
untreated or treated with 5 mM NAC or NACA for 24 hours. Following, the cells
were either subsequently treated with 100 µM DMF for an additional 5 hours, or
left alone, resulting in 6 treatment groups (control, control + DMF, NAC, NAC +
DMF, NACA or NACA + DMF).
Glutathione Quantification. Cellular protein was washed 3 times with ice cold
phosphate buffered saline (PBS) before being scraped and precipitated in 5%
sulfosalicylic acid and sonicated, while tissue was placed into the acid and
homogenized via glass mortar and pestle. Each solution was then allowed to sit
on ice for 10 minutes and centrifuged at 14,000 rpm, +4°C for 10 minutes. The
supernatant was removed and diluted 1:5 with assay buffer and then diluted 1:5
with sample diluent buffer supplied by the commercially available kit (Arbor Assay
Glutathione Fluorescent Detection Kit, Ann Arbor, MI). Glutathione standards were
prepared via adding 50 µL Glutathione Standard into a tube of 450 µL sample
diluent and vortexed. This was then serial diluted through seven other tubes using
250 µL of the mixture. 50 µL of samples, standards and a glutathione control were
pipetted in duplicate into a 96-well clear bottomed plate. 25 µL of the Thiostar
reagent was added to each sample. Total glutathione levels were quantified
according to the manufacturer’s instructions (fluorescent emission at 510 nm with
excitation at 370 nm). 25 µL of the reaction mixture was pipetted into each well
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before being read again on the plate reader. This allowed for calculations of total
and oxidized glutathione concentrations.
The pellet remaining at the bottom of the centrifuged sample was
resuspended in RIPA+ buffer and protein levels quantified via the Lowry method
(140).
Fumarate Extraction & Quantification. Fh KD and Scr differentiated N1E-115
cells were washed three times with ice-cold PBS followed by the immediate
addition of ice-cold chloroform/methanol (2:1) and scraping. After 10 min on ice,
0.2 volumes of water were added, followed by centrifugation at 3,220 g for 20 min.
The extraction was repeated, and the aqueous supernatants were dried. The
protein interface for each sample was removed for protein quantification. After
TMS derivatization of the extracts, samples were injected into an Agilent 7890A
GC system, coupled to an Agilent 5975C electron ionization mass selective
detector. Selected ion monitoring was performed for fumarate and the peak areas
obtained were normalized to the added internal standard. Absolute quantitation
was performed based on standard curves obtained from the normalized reference
standards, and the final metabolite concentrations were normalized to the protein
content of the cells. Note: Fumarate analysis was performed at DHMRI in
Charlotte, NC.
Determination of the Oxygen Consumption Rate (OCR). N1E-115 Scr and Fh
KD cells were seeded on V7 cell culture microplates coated with 0.2% gelatin at a
density of 10,000 cells/well. After 3 days in culture, the cells were differentiated for
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5 days as described above, and treated with 0, 10 or 50 µM DMF for the last 24
hours (n=8/group). The Seahorse extracellular flux analyzer XF-24 (Agilent
Technologies, INC., Santa Clara, CA), was used to measure the oxygen
consumption rate (OCR), using XF Assay Medium supplemented with 25 mM
glucose (142). After measurement of basal respiration, oligomycin (5 µg/mL),
carbonyl

cyanide

4-(trifluoromethoxy)phenylhydrazone

(0.5

µM),

rotenone/antimycin A (3 µM/4 µM) were added sequentially to determine ATP
production/proton leak, spare respiratory capacity and non-mitochondrial
respiration. After completion of the assay, the medium was removed and the cells
were immediately washed 3 times with cold PBS. The plate was stored at -70°C
prior to the measurement of the total protein content to normalize individual
measurements.
Tissue Sulfenic Acid Stabilization. Olfactory bulbs and brainstems p21 (young)
and p46 (old) mice were harvested and immediately placed into buffer containing
250 mM Hepes and 1 mM DTPA, pH to 7.7 and add 20 mM NEM, 10 mM
Dimedone, 1% Triton-X, 2 mM NaF, 2 mM SOV, 1/1000 protease inhibitor cocktail,
and 200 U/mL catalase. These were then homogenized using mortar and pestle
before being placed on a shaker for 30 minutes prior to centrifugation for 10 min
at 14,000 rpm at 4°C. The supernatant was removed to perform the Lowry method
(140) and subsequent western blotting.
Immunoblotting. 20-40 µg cell lysate protein or 20-40 µg protein from mouse
brain tissue was diluted to total volume with nano-pure deionized water and
incubated with 4X Laemmli loading buffer at 95°C for 15 minutes. The samples
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were centrifuged at 5000 rpm for 10 seconds and then loaded on 7.5%, 12% or
18% gels and electrophoresed at 200 volts for 60 minutes. The protein was
transferred to a PVDF membrane in transfer buffer (0.1% Tris Base, 20%
methanol, 79.9% nano-pure deionized water) at 250 mA for 100 minutes or 40 mM
overnight at 4°C. The membrane protein loading was visualized with Ponceau Red,
followed by blocking in 5% bovine serum albumin (BSA) or 5% 134 non-fat milk for
1 hour at room temperature, or overnight at 4°C according to the antibody
manufacturer’s recommendations. Primary polyclonal antibody to actin (sc-1616)
(1:5,000) was from Santa Cruz Biotechnology Inc. (Dallas, TX). Polyclonal
antibodies to GFAP (3670) (1:30,000), DM1A Tubulin (3873) (1:15,000) and β3
Tubulin (5666) (1:30,000) were from Cell Signaling (Danvers, MA). The anti-HNE
(HNE11-S) (1:5,000) was from Alpha Diagnostic International Inc. (San Antonia,
TX). Polyclonal antibody to glutathione (101-A) (1:2,000) was from Virogen
(Watertown, MA). Polyclonal sulfenic acid was from EMD Millipore (ABS30)
(1:15,000). The polyclonal anti-2SC antibody was prepared as described
previously (Nagai et al. 2007) (1:6,000). Polyclonal antibody to IBA-1 (016-20001)
(1:1,000) was purchased from Wako Pure Chemical Industries Ltd. (Richmond,
VA). Chemiluminescent substrate (Thermo Pierce, Rockford, IL) was utilized
followed by detection on photographic film (Denville Scientific, Metuchen, NJ).
Immunoblots were stripped (62.5 mM Tris, pH 6.8, 2% SDS and 0.7% (v/v) beta
mercaptoethanol) for 20 minutes at 67°C prior to re-probing with new primary
antibodies. Image J software (National Institute of Health) was used to quantify
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band intensity by densitometry. All immunoblots were normalized to protein
content using either actin or Coomassie.
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APPENDIX A
SEAHORSE CELL MITOCHONDRIAL RESPIRATION STESS
TEST

A)

B)

Appendix A Seahorse Cell Mitochondrial Respiration Stress Test. A)
Oligomycin, FCCP, and a combination of rotenone and antimycin A are serially
injected into the cells. These measure ATP-linked respiration, maximal
respiration, and non-mitochondrial respiration, respectively. Using these
measurements, as well as their basal respiration, proton leak and spare
respiratory capacity are calculated. B) Denotes the ETC complex that each
compound affects (143).
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APPENDIX B
BUFFER PREPARATIONS
Radio Immunoprecipitation Buffer
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2mM EDTA, 0.5% sodium
deoxycholate, 0.1% SDS, 1% Triton-X. Dissolve in 200 mL with DI water and
store at +4. On the day of use, add 2 mM sodium orthovanadate, 2 mM sodium
fluoride and protease inhibitor cocktail at 1:1000 dilution.
10x Wash Buffer
200 mM Tris-HCl pH 7.4 in 1 mL DI water. 0.05% Tween-20 was added to 1x
wash buffer.
10x Transfer Buffer
250 mM Tris-HCl and 1920 mM glycine dissolved in 1 mL DI water.
1x Transfer Buffer
700 mL DI water, 200 mL methanol and 100 mL 10x Transfer buffer.
10x SDS Running Buffer
250 mM Tris-HCl, 1920 mM glycine and 1% SDS was added to 1 mL water.
Stripping Buffer
Add 3.785 grams Tris-Base to ~400 mL nano-pure water pH 6.8. Dissolve 10
grams SDS and bring the final volume to 500 mL with nano-pure water. Before
stripping add 7 µL beta-mercaptoethanol/1 mL stripping buffer used.
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4x Laemmli Loading Buffer
Dissolve 0.969 grams Tris-Base in 10 mL nano-pure water and pH 6.8. Add
2.468 g~8rams DTT, 3.2 grams SDS, 16 mL glycerol and ~8 milligrams
bromophenol blue for color. Store at -20ºC.
Coomassie Stain
Stir 400 mL nano-pure water, 100 mL glacial acetic acid and 500 mL methanol
for 10 mins. Add 2.5 grams Coomassie Brilliant Blue R-250 (*Do not use G250*) and stir fat least 2 hours at room temperature. Filter staining solution
using a 0.45 µm Zap Cap and vacuum aspirator.
Coomassie Destain
Mix 100 mL methanol, 830 mL nano-pure water and 70 mL acetic acid.
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APPENDIX C
BEHAVIOR PROTOCOLS
Balance Beam Protocol
Set up:
1) Place beam (7mm) on an incline of 4º, with the end of the beam higher
than the starting point.
2) Add food and bedding (from the cage being used) to the ending platform.
Habituation:
Transfer mice into testing space 30-60 minutes prior to training/testing to
allow for acclimation.
Note: NACA mice did not undergo habituation.
Training:
1) Set first mouse on the platform and place the black box over them, allow
to sit for 20 seconds to acclimate.
2) Take the mouse out of the box and place on beam approximately 2-3
inches from the passage into the box, allowing the mouse to enter on its
own accord.
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3) Repeat the training at 1/3 of the way down the beam, 1/2 and 2/3 before
placing mouse at the starting point on the beam and having them
walk/run into the box (allow mouse~15 sec inside box to recuperate).
Note: Keep something under KO mice (hands, cage lid, etc) in case of
fall
4) Repeat training until the mouse is able to transverse the beam without
assistance.
Testing:
1) Allow mouse 30 seconds in the box with bedding and food for
acclimation.
2) Place mouse at the starting point on the beam, beginning timing and
counting of paw slips, ending when its nose reaches the black box.
3) Permit the mouse time to recuperate in the box (WT: 15-20 sec, KO: 3040 sec) before starting the next trial.
4) Repeat 4x per mouse, with the 3 best times used in statistics.
5) Use alcohol to clean the balance beam in between mice.
6) When switching to a mouse from a different cage, also switch the
bedding to maintain a familiar scent for the mice to run towards.
Rotarod Protocol
Set up:
1) Set the removable platforms at an angle, they will click into place, in
order for the machine to time each mouse.
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Habituation:
Transfer mice into testing space 30-60 minutes prior to training/testing to
allow for acclimation.
Note: NACA mice did not undergo habituation.
Training:
1) Place one mouse in between each set of partitions, allow to sit for one
minute, before removing them.
2) Set the rotarod to a fixed speed at 4 rpm, place the mice back onto the
machine and start the wheel, letting it rotate for one minute.
3) Set the rotarod to accelerated mode, with the minimum at 4 rpm and
max at 40 rpm, this will also be for 1 minute. The mice should always be
placed on the wheel while it is stopped.
Testing:
1) Using the accelerating function, set the minimum at 4 rpm and the max
at 40 rpm, constantly accelerating for 5 minutes.
2) Place mice on wheel, making sure the platforms are up, and begin
testing
3) When a mouse falls from the wheel and hits the platform, the time from
start to fall will be displayed on the screen.
4) Repeat this process with the next cage. One run should be performed
by each cage before beginning on the second run. Rotating through the
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cages in this way should allow mice a resting period of ~20-30 minutes,
dependent upon the number of cages
5) Mice are to be tested four times each.
6) In PLX study, each run was recorded and later analyzed for
cartwheeling. This provided the amount of time the mice spent running
versus holding on to the wheel.
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